Epicutaneous exposure to proteins and skin immune function

European Journal of Dermatology

Volumn 24, Issue 1, 2014, Pages 10-14

  Kimber, Ian ^a   Griffiths, Christopher E M ^a   Basketter, David A ^b   Mcfadden, John P ^c   Dearman, Rebecca J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b DABMEB CONSULTANCY LTD   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Allergy; IgE; Protein; Skin immune system; Skin penetration; Th2 response

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; LACTOFERRIN; PROTEIN; THYMIC STROMAL LYMPHOPOIETIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ALLERGIC DISEASE; ALLERGIC REACTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DERMATITIS; DRUG EXPOSURE; FOOD ALLERGY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LANGERHANS CELL; PLEIOTROPY; REVIEW; SKIN PENETRATION; SKIN SENSITIZATION; SKIN SURFACE; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TH17 CELL; TH2 CELL; HYPERSENSITIVITY; IMMUNOLOGY; SKIN;

HUMANS; HYPERSENSITIVITY; PROTEINS; SKIN;

EID: 84897502822     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2013.2187     Document Type: Review

References (54)

1. Kimber I, Cumberbatch M, Dearman RJ, Bhushan M, Griffiths CEM. Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. Br J Dermatol 2000; 142: 401-12.
2. Streilein JW. Antigen-presenting cells in the induction of contact hypersensitivity in mice: evidence that Langerhans cells are sufficient but not required. J Invest Dermatol 1989; 93: 443-8.
3. Kaplan DH, Jenison MC, Saeland S, Shlomchik WD, Shlomchik MJ. Epidermal Langerhans cell-deficient mice develop enhanced contact sensitivity. Immunity 2005; 23: 611-20.
4. Bobr A, Olvera-Gomez I, Igyarto BZ, Haley KM, Hogquist KA, Kaplan DH. Acute ablation of Langerhans cells enhances skin immune responses. J Immunol 2010; 185: 4724-8.
5. Bennett CL, Noordegraaf M, Martina CA, Clausen BE. Langerhans cells are required for efficient presentation of topically applied hapten to T cells. J Immunol 2007; 179: 6830-5.
6. Noordegraf M, Flacher V, Stoitzner P, Clausen BE. Functional redundancy of Langerhans cells and Langerin+ dermal dendritic cells in contact hypersensitivity. J Invest Dermatol 2010; 130: 2752-9.
7. Guilliams M, Henri S, Tamoutounour S, et al. From skin dendritic cells to a simplified classification of human and mouse dendritic cell subsets. Eur J Immunol 2010; 40: 2085-130.
8. Bursch LS, Wang L, Igyarto B, et al. Identification of a novel population of Langerin+ dendritic cells. J Exp Med 2007; 204: 3147-56.
9. Edelson BT, Wumesh KC, Juang R, et al. Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells. J Exp Med 2010; 207: 823-36.
10. Kautz-Neu K, Noordegraaf M, Dinges S, et al. Langerhans cells are negative regulators of the anti-Leishmania response. J Exp Med 2011; 208: 885-91.
11. Shklovskaya E, O'Sullivan BJ, Ng LG, et al. Langerhans cells are precommitted to immune tolerance induction. Proc Natl Acad Sci USA 2011; 108: 18049-54.
12. Yoshiki R, Kabashima K, Sugita K, Atarashi K, Shimauchi T, Tokura Y. IL-10-producing Langerhans cells and regulatory T cells are responsible for depressed contact hypersensitivity in grafted skin. J Invest Dermatol 2009; 129: 705-13.
13. Igyarto BZ, Kaplan DH. The evolving function of Langerhans cells in adaptive skin immunity. Immunol Cell Biol 2010; 88: 361-5.
14. Schwarz A, Noordegraaf M, Maeda A, Torii K, Clausen BE, Schwarz T. Langerhans cells are required for UVR-induced immunosuppression. J Invest Dermatol 2010; 130: 1419-27.
15. Fukunaga A, Khaskhely NM, Ma Y, et al. Langerhans cells serve as immunoregulatory cells by activating NKT cells. J Immunol 2010; 185: 4633-40.
16. Kaplan DH. In vivo function of Langerhans cells and dermal dendritic cells. Immunol Today 2010; 31: 446-51.
17. Klechevsky E, Morita R, Liu M, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008; 29: 497-510.
18. Cumberbatch M, Clelland K, Dearman RJ, Kimber I. Impact of cutaneous IL-10 on resident epidermal Langerhans cells and the development of polarized immune responses. J Immunol 2005; 175: 43-50.
19. Igyarto BZ, Haley K, Ortner D, et al. Skin-resident murine dendritic cell subsets promote distinct and opposing antigenic-specific T helper cell responses. Immunity 2011; 35: 260-72.
20. Loser K, Bissert S. Dendritic cells and T cells in the regulation of cutaneous immunity. Adv Dermatol 2007; 23: 307-33.
21. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol 2009; 9: 679-91.
22. Strid J, Tigelaar RE, Hayday AC. Skin immune surveillance by T cells-a new order? Semin Immunol 2009; 21: 110-20.
23. Swamy M, Jamora C, Havran W, Hayday A. Epithelial decision makers: in search of the 'epimmunome'. Nat Immunol 2010; 11: 656-65.
24. Senti G, von Moos S, Kundig TM. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy 2011; 66: 798-809.
25. Mitragotri S. Immunization without needles. Nat Rev Immunol 2005; 5: 905-16.
26. Yagi H, Hashizume H, Horibe T, et al. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. Cancer Res 2006; 66: 10136-44.
27. Hjorth N, Roed-Petersen J. Occupational protein contact dermatitis in food handlers. Contact Derm 1976; 2: 28-42.
28. Smith Pease CK, White IR, Basketter DA. Skin as a route of exposure to protein allergens. Clin Exp Dermatol 2002; 27: 296-300.
29. Amaro C, Goossens A. Immunological occupational contact urticarial and contact dermatitis from proteins: a review. Contact Derm 2008; 58: 67-75.
30. Kanerva L, Vanhanen M. Occupational and allergic contact urticaria and rhinoconjunctivitis from a detergent protease. Contact Derm 2001; 45: 49-51.
31. Doutre M-S. Occupational contact urticarial and protein contact dermatitis. Eur J Dermatol 2005; 15: 419-24.
32. Du Toit G, Katz Y, Sasieni P, et al. Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy. J Allergy Clin Immunol 2008; 122: 984-91.
33. Fox AT, Sasieni P, du Toit G, Syed H, Lack G. Household peanut consumption as a risk factor for the development of peanut allergy. J Allergy Clin Immunol 2009; 123: 417-23.
34. Chan SMH, Turcanu V, Stephen AC, Fox AT, Grieve AP, Lack G. Cutaneous lymphocyte antigen and α4β7 T-lymphocyte responses are associated with peanut allergy and tolerance in children. Allergy 2012; 67: 336-42.
35. Lack G. Update on risk factors for food allergy. J Allergy Clin Immunol 2012; 129: 1187-97.
36. Strid J, Thomson M, Hourihane J, Kimber I, Strobel S. A novel model of sensitization and oral tolerance to peanut protein. Immunology 2004; 113: 293-303.
37. Beck LA, Leung DYM. Allergen sensitization through the skin induces systemic allergic responses. J Allergy Clin Immunol 2000; 106: S258-S263.
38. Strid J, Hourihane J, Kimber I, Callard R, Strobel S. Epicutaneous exposure to peanut protein prevents oral tolerance and enhances allergic sensitization. Clin Exp Allergy 2005; 35: 757-66.
39. Hauser C, Snapper CM, Ohara J, Paul WE, Katz SI. T helper cells grown with hapten-modified cultured Langerhans cell produce interleukin 4 and stimulate IgE production by B cells. Eur J Immunol 1989; 19: 245-51.
40. Callard RE, Harper JI. The skin barrier, atopic dermatitis and allergy: a role for Langerhans cells. Trends Immunol 2007; 28: 294-8.
41. Strid J, Hourihane J, Kimber I, Callard R, Strobel S. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. Eur J Immunol 2004; 34: 2100-9.
42. Herrick CA, Xu L, McKenzie ANJ, Tigelaar RE, Bottomly K. IL-13 is necessary, not simply sufficient, for epicutaneously induced Th2 responses to soluble protein antigen. J Immunol 2003; 170: 2488-95.
43. Holgate ST. The epithelium takes centre stage in asthma and atopic dermatitis. Trends Immunol 2007; 28: 248-51.
44. Larson RP, Comeau MR, Ziegler SF. Allergen-specific CD4 T cells respond indirectly to thymic lymphopoietin to promote allergic responses in the skin. J Immunol 2013; 190: 4474-7.
45. Strid J, Sobolev O, Zafirova B, Polic B, Hayday A. The intraepithelial T cell response to NKG2D ligands links lymphoid stress surveillance to atopy. Science 2011; 334: 1293-7.
46. Yang H, Chiang BL. Novel approaches to food allergy. Clin Rev Allergy Immunol 2013; Epub
47. Cox L, Compalati E, Kundig T, Larche M. New directions in immunotherapy. Curr Allergy Asthma Rep 2013; 13: 178-95.
48. Dioszeghy V, Mondoulet L, Dhelft V, et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol 2011; 186: 5629-37.
49. Mondoulet L, Dioszeghy V, Puteaux E, et al. Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy in mice. Clin Transl Allergy 2012: 22-6.
50. Sparber F, Tripp CH, Hermann M, Romani N, Stoitzner P. Langerhans cells and dermal dendritic cells capture protein antigens in the skin: possible targets for vaccination through the skin. Immunobiol 2010; 15: 770-9.
51. Cumberbatch M, Dearman RJ, Uribe-Luna S, Headon DR, Ward PP, Conneely OM. Regulation of epidermal Langerhans cell migration by lactoferrin. Immunology 2000; 100: 21-8.
52. Almond R, Flanagan BF, Antonopoulos A, et al. Differential immunogenicity and allergenicity of native and recombinant human lactoferrins: role of glycosylation. Eur J Immunol 2013; 43: 170-81.
53. Griffiths CEM, Cumberbatch M, Tucker SC, et al. Exogenous topical lactoferrin inhibits allergen-induced Langerhans cell migration and cutaneous inflammation in humans. Br J Dermatol 2001; 144: 715-25.
54. Cumberbatch M, Bhushan M, Dearman RJ, Kimber I, Griffiths CEM. IL-1β-induced Langerhans cell migration and TNF-α production in human skin: regulation by lactoferrin. Clin Exp. Immunol 2003; 132: 352-9.